Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Bibliographic Details
Main Authors: Dent, Rebecca A, Lindeman, Geoffrey J, Clemons, Mark, Wildiers, Hans, Chan, Arlene, McCarthy, Nicole J, Singer, Christian F, Lowe, Elizabeth S, Watkins, Claire L, Carmichael, James
Format: Online
Language:English
Published: BioMed Central 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/
id pubmed-3979135
recordtype oai_dc
spelling pubmed-39791352014-04-08 Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Dent, Rebecca A Lindeman, Geoffrey J Clemons, Mark Wildiers, Hans Chan, Arlene McCarthy, Nicole J Singer, Christian F Lowe, Elizabeth S Watkins, Claire L Carmichael, James Research Article BioMed Central 2013 2013-09-25 /pmc/articles/PMC3979135/ /pubmed/24063698 http://dx.doi.org/10.1186/bcr3484 Text en Copyright © 2013 Dent et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Dent, Rebecca A
Lindeman, Geoffrey J
Clemons, Mark
Wildiers, Hans
Chan, Arlene
McCarthy, Nicole J
Singer, Christian F
Lowe, Elizabeth S
Watkins, Claire L
Carmichael, James
spellingShingle Dent, Rebecca A
Lindeman, Geoffrey J
Clemons, Mark
Wildiers, Hans
Chan, Arlene
McCarthy, Nicole J
Singer, Christian F
Lowe, Elizabeth S
Watkins, Claire L
Carmichael, James
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
author_facet Dent, Rebecca A
Lindeman, Geoffrey J
Clemons, Mark
Wildiers, Hans
Chan, Arlene
McCarthy, Nicole J
Singer, Christian F
Lowe, Elizabeth S
Watkins, Claire L
Carmichael, James
author_sort Dent, Rebecca A
title Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_short Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_full Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_fullStr Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_full_unstemmed Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
title_sort phase i trial of the oral parp inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
description
publisher BioMed Central
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979135/
_version_ 1612075462248366080

Similar Items